Essential Thrombocythemia (ET)
14
5
7
7
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
0.0%
0 terminated out of 14 trials
100.0%
+13.4% vs benchmark
14%
2 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 7 completed trials
Clinical Trials (14)
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis
Identification of MPN-specific Antigens and Anti-MPN TCRs in Myeloproliferative Neoplasm
National Longitudinal Cohort of Hematological Diseases
MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs)
MethoTRExATE in MyelOpRolifErative Neoplasms (TREATMORE) Trial
The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia
Unraveling the Role of Extracellular Vesicles-driven Senescence in Myeloproliferative Neoplasms
Assessing Feasibility of Thromboprophylaxis With Apixaban in JAK2-positive Myeloproliferative Neoplasm Patients
Screening for Asymptomatic Portal Vein Thrombosis and Portal Hypertension in Patients With Philadelphia Negative Myeloproliferative Neoplasms
Agrylin Drug Use-Result Survey
Exploratory Multi-centre Trial In Patients With ET Treated With XAGRID®
Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
Pediatric Disease Registry in Essential Thrombocythaemia (ET)